Medical Patent News

RSS

University of Mississippi grants ChromaDex global rights to pterostilbene

ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.

9 Jun 2011

Covidien files answer and counterclaims against Applied Medical for patent misuse, non-infringement

Covidien, a leading global provider of healthcare products, today announced that a subsidiary of the Company filed an answer and counterclaims against Applied Medical Resources Corporation for patent misuse, non-infringement and invalidity.

8 Jun 2011

U.S. District Court rules in favor of Boston Scientific in PROMUS patent lawsuit

Boston Scientific Corporation today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. District Court for the District of Delaware, finding all four patents in a suit involving Johnson & Johnson to be invalid.

8 Jun 2011

Incisive Surgical receives U.S. patent for INSORB Absorbable Skin Stapling Technology

Incisive Surgical, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) issued the Company a key patent for its proprietary INSORB Absorbable Skin Stapling Technology.

7 Jun 2011

Patent infringement suit filed against Impax Laboratories in connection with Detrol

Impax Laboratories, Inc. today confirms that Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol (tolterodine tartrate) immediate-release, 1 mg and 2 mg tablets.

4 Jun 2011

Medisafe 1 Technologies to submit three patent applications for medical devices

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company is in the process of submitting three patent applications for medical safety devices.

4 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Rheonix to receive U.S. patent for powerful microfluidic platform

Rheonix, Inc., developer of the Rheonix CARD system that provides a powerful microfluidic platform for the evolving molecular diagnostics industry, announced that on June 14, 2011 the U.S. Patent and Trademark Office will issue Patent Number 7,959,875, "Microfluidic Chips and Assay Systems," and on April 13, 2011 it allowed Patent Application Number 11/594,444, "Microfluidic Systems," to the Company.

3 Jun 2011

Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C

Anadys Pharmaceuticals, Inc. today announced issuance of the U.S. patent covering setrobuvir, the Company's Direct-Acting Antiviral in Phase IIb development for chronic hepatitis C virus infection.

2 Jun 2011

EPO awards Trilink patent for CleanAmp Primers

TriLink BioTechnologies, Inc., a leader in manufacturing high quality oligonucleotides and nucleoside triphosphates, announced today the award of their CleanAmp Primer patent by the European Patent Office (EPO Patent no. 2032714).

27 May 2011

Key U.S. patents increase commercial rights and clinical indications

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company’s product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.

23 May 2011

Prowess files patent infringement lawsuit against RaySearch in Baltimore court

As previously announced, RaySearch Laboratories AB has been contacted by a US company named Prowess, which claims that RaySearch has infringed on a US patent in respect of which Prowess has a license.

23 May 2011

U.S. District Court grants Cephalon Temporary Restraining Order for generic AMRIX

Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc., and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX.

21 May 2011

USPTO awards Serina patent for polymer drug delivery technology

Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.

21 May 2011

USPTO grants four key patents for Alvine's proteases to detect celiac disease

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the United States Patent and Trademark Office has issued four key patents: 7,943,312; 7,928,056; 7,923,532; and 7,910,541, protecting various aspects of Alvine's core technology.

19 May 2011

USPTO issues notice of allowance to Vermillion's Peripheral Artery Disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Panel of Biomarkers for Peripheral Artery Disease" to the company.

18 May 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.

16 May 2011

Insurer rates spark attention

In Connecticut, Aetna is proposing rate cuts for this year, a move that reflects, at least partially, the impact of the federal health law. Meanwhile, The Hill reports that consumer groups are anxiously awaiting regulations that will allow the Department of Health and Human Services to review rates. These regs are likely to be out by the end of the month.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.